Exploring Inflammatory and Metabolic Biomarkers in Sepsis

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 5131

Special Issue Editors


E-Mail Website
Guest Editor
RIKEN, Yokohama, Japan
Interests: inflammation; microenvironment; omics; hepatology

E-Mail Website
Guest Editor
Department of Intensive Care Unit, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China
Interests: sepsis; critical care; nutrition; trauma

Special Issue Information

Dear Colleagues,

We are pleased to introduce a Special Issue of the Endocrinology and Clinical Metabolic Research Section of Metabolites on “Exploring Inflammatory and Metabolic Biomarkers in Sepsis”. Sepsis is a systemic inflammatory disorder that results in lethal organ malfunction due to dysregulated host response to infection, and accounts for approximately 11 million deaths per year globally. Particularly, elderly people are more likely to rapidly develop irreversible septic shock, making it an urgent issue to develop quantitative monitoring tools and early intervention strategies for improving the QoL of those with sepsis in the super-aging society.

There is increasing interest in the roles of dysregulated signals and metabolites of the inflammatory microenvironment (e.g., extravasated platelet aggregation and persistent immune dysfunction of locally infected foci) in the pathophysiology of sepsis. These findings highlight a novel avenue to explore novel biomarkers for sepsis by focusing on the special inflammatory response and metabolic reprogramming in the pathogenesis of sepsis.

The aim of this Special Issue is to establish a collection of evidence on the signals and metabolic features of the inflammatory response and metabolic reprogramming in the pathogenesis of sepsis. This Research Topic aims to make a significant contribution to the literature in order to inform further efforts in promoting clinical research into biomarker-based precision medicine for the prevention and therapy of sepsis. We welcome submissions of original research, review and perspective articles from both clinical and basic research.

Dr. Xian-Yang Qin
Dr. Wenkui Yu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sepsis
  • inflammation
  • metabolic reprogramming
  • microenvironment
  • biomarker

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1820 KiB  
Article
Serum Metabolomic Profiles in Critically Ill Patients with Shock on Admission to the Intensive Care Unit
by Aurélie Thooft, Raphaël Conotte, Jean-Marie Colet, Karim Zouaoui Boudjeltia, Patrick Biston and Michaël Piagnerelli
Metabolites 2023, 13(4), 523; https://doi.org/10.3390/metabo13040523 - 05 Apr 2023
Viewed by 945
Abstract
Inflammatory processes are common in intensive care (ICU) patients and can induce multiple changes in metabolism, leading to increased risks of morbidity and mortality. Metabolomics enables these modifications to be studied and identifies a patient’s metabolic profile. The objective is to precise if [...] Read more.
Inflammatory processes are common in intensive care (ICU) patients and can induce multiple changes in metabolism, leading to increased risks of morbidity and mortality. Metabolomics enables these modifications to be studied and identifies a patient’s metabolic profile. The objective is to precise if the use of metabolomics at ICU admission can help in prognostication. This is a prospective ex-vivo study, realized in a university laboratory and a medico-surgical ICU. Metabolic profiles were analyzed by proton nuclear magnetic resonance. Using multivariable analysis, we compared metabolic profiles of volunteers and ICU patients divided into predefined subgroups: sepsis, septic shock, other shock and ICU controls. We also assessed possible correlations between metabolites and mortality. One hundred and eleven patients were included within 24 h of ICU admission, and 19 healthy volunteers. The ICU mortality rate was 15%. Metabolic profiles were different in ICU patients compared to healthy volunteers (p < 0.001). Among the ICU patients, only the subgroup of patients with septic shock had significant differences compared to the ICU control patients in several metabolites: pyruvate, lactate, carnitine, phenylalanine, urea, creatine, creatinine and myo-inositol. However, there was no correlation between these metabolite profiles and mortality. On the first day of ICU admission, we observed changes in some metabolic products in patients with septic shock, suggesting increased anaerobic glycolysis, proteolysis, lipolysis and gluconeogenesis. These changes were not correlated with prognosis. Full article
(This article belongs to the Special Issue Exploring Inflammatory and Metabolic Biomarkers in Sepsis)
Show Figures

Figure 1

16 pages, 3258 KiB  
Article
Akkermansia muciniphila Alleviates Persistent Inflammation, Immunosuppression, and Catabolism Syndrome in Mice
by Yali Xu, Jianfeng Duan, Dacheng Wang, Jiali Liu, Xiancheng Chen, Xian-Yang Qin and Wenkui Yu
Metabolites 2023, 13(2), 194; https://doi.org/10.3390/metabo13020194 - 28 Jan 2023
Cited by 5 | Viewed by 1799
Abstract
Many patients in intensive care units, especially the elderly, suffer from chronic critical illness and exhibit a new pathophysiological phenotype: persistent inflammation, immunosuppression, and catabolism syndrome (PICS). Most patients with PICS have a constellation of digestive-system symptoms and gut failure. Akkermansia muciniphila (Akk) [...] Read more.
Many patients in intensive care units, especially the elderly, suffer from chronic critical illness and exhibit a new pathophysiological phenotype: persistent inflammation, immunosuppression, and catabolism syndrome (PICS). Most patients with PICS have a constellation of digestive-system symptoms and gut failure. Akkermansia muciniphila (Akk) is a commensal gut bacterium that reduces inflammation, balances immune responses, modulates energy metabolism, and supports gut health. This study investigated the protective effects and underlying mechanisms of live and pasteurized Akk in treating PICS in a mouse model. PICS was induced on day 14 after performing cecal ligation and puncture (CLP) on day 1 and administrating lipopolysaccharide on day 11. Pasteurized or live Akk, or phosphate-buffered saline was administered twice daily by oral gavage for 7 days. Both live and pasteurized Akk attenuated PICS, as evidenced by reduced weight loss, and a reduction in symptoms and serum cytokine/chemokine levels. Liver and intestinal injuries were mitigated, and intestinal barrier integrity improved with Akk administration. Analysis of 16S rRNA amplicon sequences showed that Akk induced significant intestinal microbiota alterations, including increased abundance of Akk, Muribaculaceae, Parabacterbides goldsteinii, and decreased abundance of Escherichia_Shigella and Enterobacteriaceae. Collectively, Akk alleviates PICS by enhancing gut barrier function and reshaped the microbial community. Full article
(This article belongs to the Special Issue Exploring Inflammatory and Metabolic Biomarkers in Sepsis)
Show Figures

Figure 1

21 pages, 1486 KiB  
Article
Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles
by Knut Anders Mosevoll, Bent Are Hansen, Ingunn Margareetta Gundersen, Håkon Reikvam, Øyvind Bruserud, Øystein Bruserud and Øystein Wendelbo
Metabolites 2023, 13(1), 52; https://doi.org/10.3390/metabo13010052 - 29 Dec 2022
Cited by 2 | Viewed by 1800
Abstract
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. In the present study, we investigated the systemic/serum lipidomic profile at the time of hospital admission for patients with bacterial sepsis. The study included 60 patients; 35 patients [...] Read more.
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. In the present study, we investigated the systemic/serum lipidomic profile at the time of hospital admission for patients with bacterial sepsis. The study included 60 patients; 35 patients fulfilled the most recent 2016 Sepsis-3 criteria (referred to as Sepsis-3) whereas the remaining 25 patients had sepsis only according to the previous Sepsis-2 definition and could be classified as having Systemic Inflammatory Response Syndrome (SIRS). A total of 966 lipid metabolites were identified. Patients fulfilling the Sepsis-3 criteria differed from the Sepsis-2 patients with regard to only 15 lipid metabolites, and especially sphingolipids metabolism differed between these patient subsets. A total of only 43 metabolites differed between patients with and without bacteremia, including 12 lysophosphatidylcholines and 18 triacylglycerols (15 C18/C20 fatty acid metabolites decreased and three C14 myristate acid metabolites that were increased in bacteremia). Unsupervised hierarchical clustering analyses based on the identified sphingolipids, phosphatidylcholine and triacylglycerols showed that (i) the majority of Sepsis-3 patients differed from SIRS patients especially with regard to lysophosphatidylcholine levels; (ii) the minority of Sepsis-3 patients that clustered together with the majority of SIRS patients showed lower Sequential Organ Failure Assessment (SOFA) scores than the other Sepsis-3 patients; and (iii) the variation between the patients in the identified/altered sphingolipid and triacylglycerol metabolites further increased the heterogeneity of Sepsis-3 patients with regard to their systemic lipidomic profile at the time of diagnosis. To conclude, patients fulfilling the Sepsis-3 criteria differ with regard to their metabolic profile, and this variation depends on disease severity. Full article
(This article belongs to the Special Issue Exploring Inflammatory and Metabolic Biomarkers in Sepsis)
Show Figures

Figure 1

Back to TopTop